Glycovax Pharma
Press releases
Glycovax Pharma commercializes an outstanding CRM197
The new performant carrier protein developed under license
from the National Research Council Canada.
Glycovax Pharma launches a highly performant SLA Adjuvant
Developed through a licence from the
National Research Council Canada
Glycovax Pharma develops a vaccine to fight Pa-related infections
Glycovax Pharma, NRC, and Université de Montréal are collaborating to develop a vaccine against Pseudomonas aeruginosa, a bacterium causing severe infections in cystic fibrosis patients.